By Dr Jia (Jenny) Liu

Book Chapters

Liu J; Ward RL, 2010, 'Folate and one-carbon metabolism and its impact on aberrant DNA methylation in cancer', in Herceg Z; Ushijima T (ed.), Advances in Genetics, Elsevier Inc, Burlington, pp. 79 - 122

Journal articles

Childs S; Ma D; Houghton E; Cosman R; Massey J; Chin V; Valencia V; O’Grady A; Jensen SK; McLaughlin A; Goodwin S; Tao H; Withers B; Noakes C; Horne A; Preisz P; Boyd J; Forstner D; Rodrigues A; Sandhu G; Ibrahim K; Martin C; Kwan B; De Luca N; Buscher H; Cunningham P; Joshua AM; Girgis L; Tran B; Desai J; Harrison SJ; Moore J; Liu J, 2026, 'A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases', Npj Precision Oncology, 10, http://dx.doi.org/10.1038/s41698-026-01462-6

Liu J; Farrow M; Hsing SS; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson AO; Park JJW; Rodrigues A; Chan WY; Wei J; Cohen J; Underhill CR; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance', Clinical Cancer Research an Official Journal of the American Association for Cancer Research, 32, pp. 3991 - 4000, http://dx.doi.org/10.1158/1078-0432.CCR-26-0733

Farahnak F; El-Deiry WS; Lussier YA; Kurzrock R; Magidi S; Bresson C; Enger SA; Liu J; Bar J; Warner JL; Meissner T; Rubin E; Rueter J; Gaddipati H; Kulkarni M; Chen Z; Limaye S; Elsey R; Rubenstein BM; Joshua AM; Al-Shamsi HO; Musallam KM; Wunder F; Raynaud J; Berchem G; Gantenbein M; Al Omari A; Dermime S; Abdel-Razeq H; Saintigny P; Cervantes A; Reddel RR; Aref AT; Martin-Liberal J; Lázaro C; Romera DC; Sekacheva M; Berger R; Pramesh CS; Berindan-Neagoe I; Girda E; Piris-Gimenez A; Farhangfar CJ; Salem ME; Dienstmann R; Salazar R; Frankel NZ; Batist Z; Quintana Y; Batist G, 2026, 'Worldwide Innovative Network Consortium: Building a Common Global Cancer Database', JCO Global Oncology, 12, http://dx.doi.org/10.1200/GO-25-00720

Liu J; Farrow M; Hsing S; Cosman R; Lemech CR; Teng C; Pal A; Nindra U; Parsonson A; Park JJ; Rodrigues A; Chan W; Wei J; Cohen J; Underhill C; Brungs D; Hui M; Nagrial A; Jain S; Joshua AM, 2026, 'Abstract A056: Network-integrated clinical trial navigation with ctDNA profiling improves early-phase trial access: Final results from the PANNA-COTA study', Clinical Cancer Research, 32, pp. a056 - a056, http://dx.doi.org/10.1158/1557-3265.d32026-a056

McNamee N; Aref A; Poulos R; Craft G; Koh J; Xavier D; Singh A; Kansara M; Robinson P; Hains P; Ballinger M; Liu JJ; Thomas D; Reddel R, 2026, 'Abstract B051: Targeted proteomics for parallel ADC biomarker screening: a pilot feasibility study within an Australian precision oncology program', Clinical Cancer Research, 32, pp. b051 - b051, http://dx.doi.org/10.1158/1557-3265.d32026-b051

Liu J; Beal J; Coleman N; Ma BBY; Loong HH; Zhao H; Seymour L; Westphalen CB; Curigliano G; Subbiah V, 2026, 'Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation', Journal of Clinical Oncology, 44, pp. 1933 - 1944, http://dx.doi.org/10.1200/JCO-26-00034

Smith NJ; Gunasegaran B; McLean A; Kohonen-Corish MRJ; Bucca A; Checkley J; Lee JH; Liu J; Kao S; Boyer M; Mander K; Brown B; Wang XS; O’Sullivan JF; Fazekas de St Groth B; McGuire HM, 2026, 'Integrated cellular, proteomic and metabolomic profiling of immune-related adverse events in non-small cell lung cancer', Frontiers in Immunology, 17, http://dx.doi.org/10.3389/fimmu.2026.1911262

Jones RH; Pinato DJ; Forster MD; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu J; Cosman R; Benafif S; Edmondson SR; Paull JRA; Main NJ; Angeles J; Spicer J, 2026, 'Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours', European Journal of Cancer, 242, http://dx.doi.org/10.1016/j.ejca.2026.116821

Corry J; Brungs D; Liu J; McDowell L; Thornton R; Mar G; Nicholls T; Ooi EH, 2026, 'Multidisciplinary Care of Locally Advanced Mucosal Head and Neck Cancer: An Australian Perspective', Asia Pacific Journal of Clinical Oncology, 22, pp. 351 - 361, http://dx.doi.org/10.1111/ajco.70005

Smith A; Girgis A; Taylor N; Pearce A; Liu J; Shepherd HL; Wu VS; Garvey G; Kirsten L; Zakhary I; Ee C; Ewald D; Miller A; Shaw J, 2026, 'Step-by-step: A clinical pathway for stepped care management of fear of cancer recurrence—results of a three-round online delphi consensus process with Australian health professionals and researchers', Journal of Cancer Survivorship, 20, pp. 766 - 780, http://dx.doi.org/10.1007/s11764-024-01685-1

Liu J; LoRusso P, 2026, 'When herds overgraze: the cost of conformity in oncology drug development', BMJ Oncology, 5, http://dx.doi.org/10.1136/bmjonc-2026-001089

Nindra U; Shivasabesan G; Mellor R; Chua W; Karikios D; Richards B; Liu J, 2026, 'Much ado about mentorship: a qualitative analysis of participant feedback from the inaugural Australian National Oncology Mentorship Programme', Internal Medicine Journal, 56, pp. 417 - 424, http://dx.doi.org/10.1111/imj.70328

McNamee NJ; Liu J; Poulos RC; Aref AT; Reddel RR, 2026, 'Predictive Biomarkers of Antibody–Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics', Clinical Cancer Research, 32, pp. 661 - 673, http://dx.doi.org/10.1158/1078-0432.CCR-25-3103

Varkaris A; Italiano A; Sammons S; Falgas EF; Schram AM; Pistilli B; Schott A; Ortega PT; Wisinski K; Wei M; Nanda R; McGuinness JE; Ahnert JR; Ehsani S; Liu JJ; Timm A; Shen J; Kwak EL; Manich CS; Curigliano G, 2026, '90O Dose optimization of zovegalisib, a novel PI3Kα inhibitor, in patients (pts) with PIK3CA-mutant (m) HR+/HER2− advanced breast cancer (BC): Results from the first-in-human (FIH) study to support the recommended phase III dose', ESMO Open, 11, pp. 106232, http://dx.doi.org/10.1016/j.esmoop.2026.106232

Cohen JE; Taylor N; Webster AC; Liu J, 2026, 'Decentralised oncology trials: decentralisation as a tool, not the goal', BMJ Oncology, 5, pp. e001255, http://dx.doi.org/10.1136/bmjonc-2026-001255

Liu J; Beal J; Coleman N; Lynam J; Subbiah V, 2026, 'Tumour-agnostic immunotherapy: aligning biological rationale, biomarker precision, and real-world implementation', eClinicalMedicine, 100, pp. 104211 - 104211, http://dx.doi.org/10.1016/j.eclinm.2026.104211

Tyne T; Ivimey E; Duggan L; Liu J, 2025, 'A personal perspective of patient-centred clinical trials', Oncotarget, 16, pp. 808 - 812, http://dx.doi.org/10.18632/oncotarget.28776

Liu J; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Yau W; Aktas BY; Cosman R; Cohen JE; Edmondson SR; Paull JRA; Jean-Francois BM; Main NJ; Angeles J; Castellarnau A; Cook N, 2025, 'Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors', Journal of Clinical Oncology, 43, pp. 2918 - 2929, http://dx.doi.org/10.1200/JCO-25-00236

Liu J; Yang J; Sun Y; Gong J; Yue J; Pan Y; Sun M; Song R; Xiao X; Tazbirkova A; Ruan J; Liu Z; Liu Z; Li Z; Sheng L; Qin Y; Ying J; Yu X; Zhang J; Mou Y; Lu C; Chen P; Li S; Li J; Qu X; Deng T; Du J; Zhou A; Li E; Yuan X; Liang X; Yu W; Morris M; Luo Y; Zhao X; Guo Y; Zhou H; Shen L, 2025, 'CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial', Nature Medicine, 31, pp. 3028 - 3036, http://dx.doi.org/10.1038/s41591-025-03783-8

Cai Z; Boys EL; Noor Z; Aref AT; Xavier D; Lucas N; Williams SG; Koh JMS; Poulos RC; Wu Y; Dausmann M; Mackenzie KL; Aguilar-Mahecha A; Armengol C; Barranco MM; Basik M; Bowman ED; Clifton-Bligh R; Connolly EA; Cooper WA; Dalal B; Defazio A; Filipits M; Flynn PJ; Dinny Graham J; George J; Gill AJ; Gnant M; Habib R; Harris CC; Harvey K; Horvath LG; Jackson C; Kohonen-Corish MRJ; Lim E; Liu J; Long GV; Lord RV; Mann GJ; McCaughan GW; Morgan L; Murphy L; Nagabushan S; Nagrial A; Navinés J; Panizza BJ; Samra JS; Scolyer RA; Souglakos J; Swarbrick A; Thomas D; Balleine RL; Hains PG; Robinson PJ; Zhong Q; Reddel RR, 2025, 'Federated Deep Learning Enables Cancer Subtyping by Proteomics', Cancer Discovery, 15, pp. 1803 - 1818, http://dx.doi.org/10.1158/2159-8290.CD-24-1488

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', Journal of Clinical Oncology, 43, pp. 2591 - 2591, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.2591

Wong M; Tebbutt N; Price T; Mendis S; Al-Asady R; Hsu E; Shafren D; Zdanska O; Liu J, 2025, 'Abstract CT115: Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS) colorectal,gastroesophageal or ovarian cancer', Cancer Research, 85, pp. ct115 - ct115, http://dx.doi.org/10.1158/1538-7445.am2025-ct115

Chaffer CL; Milioli HH; San Juan BP; Dear RF; Liu JJ, 2025, 'Abstract 4744: State-gating cancer to prevent chemotherapy-resistance', Cancer Research, 85, pp. 4744 - 4744, http://dx.doi.org/10.1158/1538-7445.am2025-4744

Jackson CC; Liu JJ; Liu HY; Williams SG; Anees A; Noor Z; Lucas N; Xavier D; Hains PG; Bucio-Noble D; Aref AT; Porceddu SV; Ladwa R; Whitfield J; Reddel RR; Zhong Q; Panizza BJ; Robinson PJ, 2025, 'A Proteomic Signature for Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma Predicts Patients at High Risk of Recurrence', Cancer Research Communications, 5, pp. 580 - 593, http://dx.doi.org/10.1158/2767-9764.CRC-23-0460

Liu J; Farrow M; Seymour L; Desai J; Loong HH; Ivy P; Koyoma T; Cook N; Blagden S; Garralda E; Massard C; Tolcher AW; Adashek JJ; Zhang L; Zhao S; Shen L; Kurzrock R; El-Deiry WS; Subbiah V; Joshua AM, 2025, 'Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials', Journal of Clinical Oncology, 43, pp. 735 - 747, http://dx.doi.org/10.1200/JCO-24-01534

Nindra U; Shivasabesan G; Mellor R; Ng W; Chua W; Karikios D; Richards B; Liu J, 2025, 'Final results of the National Oncology Mentorship Program 2023 and its impact on burnout and professional fulfilment', Internal Medicine Journal, 55, pp. 233 - 240, http://dx.doi.org/10.1111/imj.16574

Pham JP; Staeger R; Joshua AM; Liu J; da Silva IP; Dummer R; Goldinger SM, 2025, 'An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115121

Shekar S; Hall A; Pham J; Crumbaker M; Liu J; Talmor B; Sim HW; Joshua AM, 2025, 'Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials', Endocrine Oncology, 5, http://dx.doi.org/10.1530/EO-25-0027

Ladwa R; McLean LS; McGrath M; Liu J, 2025, 'The evolving role of immune checkpoint inhibitors in cutaneous squamous cell carcinoma: Across the disease spectrum', Ejc Skin Cancer, 3, http://dx.doi.org/10.1016/j.ejcskn.2025.100767

El-Deiry WS; Bresson C; Wunder F; Carneiro BA; Dizon DS; Warner JL; Graff SL; Azzoli CG; Wong ET; Cheng L; Mani SA; Safran HP; Williams C; Meissner T; Solomon B; Rubin E; Porgador A; Berchem G; Saintigny P; Onn A; Bar J; Berger R; Gantenbein M; Chen Z; de Pádua Souza C; Reis RMV; Sekacheva M; Cervantes A; Dahut WL; Annunziata CM; Gober K; Musallam KM; Al-Shamsi HO; Abu-Gheida I; Salazar R; Limaye S; Aref AT; Reddel RR; Al Homsi MU; Rouf A; Dermime S; Al Suwaidi J; Vlad C; Buiga R; Al Omari A; Abdel-Razeq H; Oñate-Ocaña LF; Nielsen FC; Graham L; Rueter J; Joshua AM; Girda E; Libutti S; Riedlinger G; Salem ME; Farhangfar CJ; Mesa RA; Faltas BM; Elemento O; Pramesh CS; Sengar M; Aoyama S; Ikeda S; Berindan-Neagoe I; Gaddipati H; Kulkarni M; Auzias E; Gerogianni M; Wolikow N; Istolainen S; Schlafrig P; Frankel NZ; Ferraro AR; Palma J; Gimenez AP; Hernando-Calvo A; Felip E; Tsimberidou AM; Herbst RS; Tabernero J; Schilsky RL; Liu J; Lussier Y; Raynaud J; Batist G; Magidi S; Kurzrock R, 2025, 'Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients', Oncotarget, 16, pp. 140 - 162, http://dx.doi.org/10.18632/oncotarget.28703

Liu JJ; Farrow M; Hsing S; Cosman R; Lemech C; Teng C; Pal A; Nindra U; Parsonson A; Park JJW; Underhill CR; Hui MN; Nagrial A; Jain SS; Joshua AM, 2025, '991P PANNA-COTA (Practical assessment of NECTA network assistance in cancer outpatient trials access): A prospective investigator-led trial using ctDNA to inform early phase trial matching', Annals of Oncology, 36, pp. s649, http://dx.doi.org/10.1016/j.annonc.2025.08.1560

Yu X; Ying J; Enxiao L; Zhou A; Sun Y; Yue J; Ruan J; Zhang J; Shen L; Du J; Tazbirkova A; Liu J; Qin Y; Morris MF; Li Z; Sun M; Pan Y; Zhang J; Guo Y; Zhou H, 2025, 'Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343.', Journal of Clinical Oncology, 43, pp. 4017 - 4017, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.4017

Sammons SL; Manich CS; Italiano A; Schram AM; Ortega PT; Schott AF; Guerrero A; Aix SP; Nanda R; Wisinski KB; Segar JM; Wei M; Liu J; Spira AI; McGuinness JE; Ahnert JR; X. C; Sirvén MB; Curigliano G; Varkaris A, 2025, 'Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial.', Journal of Clinical Oncology, 43, pp. 1086 - 1086, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.1086

Pham JP; Zdanska O; Selga M; Javier J; O'Grady A; Chin V; Forstner D; Hsu E; Liu J, 2024, 'Onkolytische Viren zur Verstärkung der PD-1-Hemmung bei metastasierendem kutanem Plattenepithelkarzinom', JDDG Journal of the German Society of Dermatology, 22, pp. 1016 - 1019, http://dx.doi.org/10.1111/ddg.15423_g

Dear RF-G; Liu JJ; Cosman R; Walsh N; Selga M; Perez San Juan B; Purcell C; Chaffer CL, 2024, '4CAST: A phase 1b dose exploration, open-label, single-center study evaluating the safety of INO-464 in combination with chemotherapy in patients with metastatic breast cancer.', Journal of Clinical Oncology, 42, pp. e13112 - e13112, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e13112

Liu JJ; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Aktas BY; Cosman R; Chwialkowska D; Paull J; Main NJ; Jean-Francois BM; Le Meur J; Edmondson SR; Cook N, 2024, 'Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.', Journal of Clinical Oncology, 42, pp. 3014 - 3014, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3014

Spicer JF; Pinato DJ; Forster M; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu J; Cosman R; Main NJ; Le Meur J; Paull J; Edmondson SR; Jones RH, 2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).', Journal of Clinical Oncology, 42, pp. 3004 - 3004, http://dx.doi.org/10.1200/JCO.2024.42.16_suppl.3004

Lillie T; Kichenadasse G; Liu JJ; Hernandez Guerrero T; Calvo E; Jakobsson H; Moreno V; Gan HK; Joyce P; Hyland N; Giovannetti M; Palmer T; McAlpine C; Green D; Symeonides SN, 2024, 'EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies.', Journal of Clinical Oncology, 42, pp. 2589 - 2589, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.2589

Nindra U; Shivasabesan G; Mellor R; Chua W; Ng W; Karikios D; Richards B; Liu J, 2024, 'Evaluating Systemic Burnout in Medical Oncology Through a National Oncology Mentorship Program', JCO Oncology Practice, 20, pp. 549 - 557, http://dx.doi.org/10.1200/OP.23.00469

Pham JP; Rodrigues A; Goldinger SM; Sim H-W; Liu JJ, 2024, 'Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta-analysis', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14978

Lemech C; Kichenadasse G; Teng C; Nagrial A; Richardson G; Humphries TG; Killen AJ; Joshua A; Liu JJ; Churchill M; Barnett M; Cioffi M; Cosman R, 2024, '676TiP MYE Symphony: A first-in-human study to investigate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the in vivo mRNA CAR therapy, MT-302, targeting TROP2 in adults with advanced epithelial tumors', Annals of Oncology, 35, pp. s528, http://dx.doi.org/10.1016/j.annonc.2024.08.742

Lemech C; Luke JJ; Falchook GS; Mckean M; Kichenadasse G; Teng C; Vandross AL; Salkeni MA; Atkinson VG; Liu JJ; Kennedy AM; Clark J; Ryan M; Schmidt-Kittler O; Steinhubel D; Wages D; Komarnitsky P; Puzanov I, 2024, '678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations', Annals of Oncology, 35, pp. s528 - s529, http://dx.doi.org/10.1016/j.annonc.2024.08.744

Pham JP; Zdanska O; Selga M; Javier J; O'Grady A; Chin V; Forstner D; Hsu E; Liu J, 2024, 'Oncolytic viruses to augment PD-1 inhibition in metastatic cutaneous squamous cell carcinoma', JDDG - Journal of the German Society of Dermatology, 22, pp. 1016 - 1018, http://dx.doi.org/10.1111/ddg.15423

Boys EL; Gao B; Grimison P; Sutherland S; MacKenzie KL; Reddel RR; Liu J, 2024, 'Retrospective analysis of clinical characteristics and outcomes of patients with carcinoma of unknown primary from three tertiary centers in Australia', Cancer Medicine, 13, pp. e7052 - e7052, http://dx.doi.org/10.1002/cam4.7052

Liu J; He S; Butow P; Shaw J; McHardy CJ; Harris G; Serafimovska A; Butt Z; Beith J, 2023, 'A novel clinician-delivered intervention to reduce fear of recurrence in breast cancer survivors: Results from a Phase I/II implementation study (CIFeR_2)', Psycho Oncology, 32, pp. 1930 - 1938, http://dx.doi.org/10.1002/pon.6249

Liu J; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Gaus A; Yau W; Cosman R; Chwialkowska D; Paull JRA; Jean-Francois BM; Fairley JK; Main NJ; Edmondson SR; Cook N, 2023, 'Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours', Molecular Cancer Therapeutics, 22, pp. b039 - b039, http://dx.doi.org/10.1158/1535-7163.targ-23-b039

Liu J; Serafimovska A; He S; Butow P; Shaw J; McHardy CJ; Harris G; Butt Z; Beith J, 2023, 'Protocol of an implementation study of a clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 implementation study)', BMC Medical Education, 23, http://dx.doi.org/10.1186/s12909-023-04279-0

Liu JJ; Jackson C; Anees A; Noor Z; Williams S; Porceddu S; Liu H; Ladwa R; Whitfield J; Reddel RR; Zhong Q; Panizza BJ; Robinson PJ, 2023, 'A proteomic signature associated with prognosis in HPV-related locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).', Journal of Clinical Oncology, 41, pp. 6055 - 6055, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6055

Zdanska O; Joshua AM; Liu JJ; Zdansky P; Stanners M; Rogers C, 2023, 'Cancer survivorship: Patient experiences on early phase trials during the COVID-19 pandemic—Qualitative study from an Australian Phase 1 unit.', Journal of Clinical Oncology, 41, pp. e24202 - e24202, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e24202

Back to profile page